logo
SEHK:1952 logo

Everest Medicines Community

SEHK:1952 Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

1952 logo
Everest Medicines
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts

NRDL Approval And Pipeline Efforts Will Counterbalance Potential Risks

Key Takeaways Dependence on NEFECON's success and market strategies in the IgAN space may not deliver the expected revenue, posing financial risks. Heavy investments in sales and R&D could strain margins if they fail to generate proportional revenue growth, impacting near-term earnings.
View narrative
HK$48.40
FV
0.2% undervalued intrinsic discount
68.86%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
about 1 month ago author updated this narrative